Duttaroy A, Voelker F, Ren X, et al. Head-to-head comparison of the DPP-4 inhibitor vildagliptin with exendin-4 in a model of pancreatic beta-cell injury. Presented at the American Diabetes Association Scientific Sessions, 2005b. Abstract 267-OR. Available at: http://scientificsessions.diabetes.org/Abstracts/ index.cfm (accessed December 12, 2005). EDPG (European Diabetes Policy Group). A desktop guide to type 2 diabetes. International Diabetes Federation European Region. Diabetic Med. 1999;16:716–730. El-Ouaghlidi A, Rehring E, Holst JJ, Schweizer A, Holmes D, Nauck MA. Reduced increments in total glucagon-like peptide 1 (GLP-1) and gastric inhibitory polypeptide (GIP) in plasma after a single dose of the dipeptidyl peptidase-4 inhibitor LAF237 before an oral glucose load in healthy subjects. Presented at the European Association for the Study of Diabetes Annual Meeting, 2004. Abstract 786. Available at: http://212.144.4.93/easd/ UpApplications/UpTables/provisionalprogram/groupviewpage.asp (accessed December 12, 2005). El-Ouaghlidi A, Rehring E, Schweizer A, Holmes D, Nauck M. The dipeptidyl peptidase IV inhibitor LAF 237 does not accentuate reactive hypoglycemia caused by the sulfonylurea glibenclamide administered before an oral glucose load in healthy subjects. Diabetes. 2003;52 (Suppl. 1):A118. Abstract 507-P. Fonseca V, Dejager S, Albrecht D, Shao Q, Schweizer A. Sustained efficacy and reduced hypoglycaemia with vildagliptin added to insulin in patients with type 2 diabetes. Presented at the European Association for the Study of Diabetes Annual Meeting, 2006. Abstract 0802. Available at: http://www.easd. org/ (accessed October 11, 2007). Fonseca V, Schweizer A, Albrecht D, Baron MA, Chang I, Dejager S. Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes. Diabetologia. 2007;50:1148–1155. Fox CS, Larson MG, Leip EP, Meigs JB, Wilson PW, Levy D. Glycemic status and development of kidney disease: the Framingham Heart Study. Diabetes Care. 2005;28:2436–2440. Garber AJ, Camisasca R-P, Jauffret S, Baron MA. Efficacy and tolerability of vildagliptin added to a sulfonylurea (SU) in patients with type 2 diabetes (T2DM). Presented at the American Diabetes Association Annual Meeting, 2007a. Abstract 0501-P. Available at: http://scientificsessions.diabetes.org/ Abstracts/index.cfm (accessed October 11, 2007). Garber AJ, Schweizer A, Baron MA, Rochotte E, Dejager S. Vildagliptin in combination with pioglitazone improves glycaemic control in patients with type 2 diabetes failing thiazolidinedione monotherapy: a randomized, placebo- controlled study. Diabetes, Obesity and Metabolism. 2007b;9:166–174. Goeke B, Schweizer A, Couturier A, LeBeaut A, Dejager S. Sustained efficacy and tolerability of vildagliptin monotherapy during one-year treatment of drug-naïve patients with type 2 diabetes. Presented at the European Association for the Study of Diabetes Annual Meeting, 2006. Abstract 0042. Available at: http://www.easd.org/ (accessed October 11, 2007). Gray A, Raikou M, McGuire A, et al; United Kingdom Prospective Diabetes Study Group. Cost effectiveness of an intensive blood glucose control policy in patients with type 2 diabetes: economic analysis alongside randomised controlled trial (UKPDS 41). BMJ. 2000;320:1373–1378. Hjøllund KR, Hughes TE, Holst JJ. The dipeptidyl peptidase 4 inhibitor vildagliptin has no acute effect on the endocrine secretion in the isolated perfused porcine pancreas. Presented at the European Association for the Study of Diabetes Annual Meeting, 2007. Abstract 0691. Available at: http://www.easd.org/ (accessed March 4, 2008). Hogan P, Dall T, Nikolov P; American Diabetes Association. Economic costs of diabetes in the US in 2002. Diabetes Care. 2003;26:917–932. Holman RR. Assessing the potential for alpha-glucosidase inhibitors in prediabetic states. Diabetes Res Clin Pract. 1998;40(Suppl):S21–S25. Holst JJ, Deacon CF. Glucagon-like peptide-1 mediates the therapeutic ac- tions of DPP-IV inhibitors. Diabetologia. 2005;48:612–615. Holst JJ, Gromada J. Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans. Am J Physiol Endocrinol Metab. 2004;287:E199–E206. Hughes TE, Russell ME, Bolognese L, et al. NVP-LAF237, a highly selective and long-acting dipeptidyl peptidase IV inhibitor. Diabetes. 2002;51(Suppl. 2):A67. Abstract 272-OR. Core Evidence 2008;3(1) Vildagliptin | place in therapy review IDF (International Diabetes Federation). Diabetes Prevelance. 2005a. Available at http://www.idf.org/home/index.cfm?node=264 (accessed November 7, 2005). IDF. Global guideline for type 2 diabetes. 2005b. Available at http://www.idf. org/home/index.cfm?node=1457 (accessed October 16, 2007). Jellinger PS, Davidson JA, Blonde L, et al. Road maps to achieve glycemic control in type 2 diabetes mellitus: ACE/AACE Diabetes Road Map Task Force. Endocr Pract. 2007;13:260–268. Jonsson B. CODE-2 Advisory Board. Revealing the cost of Type II diabetes in Europe. Diabetologia. 2002;45:S5–S12. Kahn R, Buse J, Ferrannini E, Stern M; American Diabetes Association; European Association for the Study of Diabetes. The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2005;28:2289–2304. Kelley DE, Dunning BE, Ligueros-Saylan M, Holst JJ, Deacon CF, Foley JE. Four-week treatment with vildagliptin increases fasting plasma levels of intact incretin hormones both in patients with type 1 (T1DM) and type 2 (T2DM) diabetes. Presented at the American Diabetes Association Annual Meeting, 2006. Abstract 1481-P. Available at: http://scientificsessions.diabetes.org/ Abstracts/index.cfm (accessed October 11, 2007). Kikuchi M, Abe N, Kato M, Terao S, Holmes D, Mimori N. Vildagliptin decreases HbA1c after 12 weeks treatment in Japanese patients with type 2 diabetes. Presented at the European Association for the Study of Diabetes Annual Meeting, 2006. Abstract 0789. Available at: http://www.easd.org/ (accessed October 11, 2007). Kimmel B, Inzucchi SE. Oral agents for type 2 diabetes: an update. Clinical Diabetes. 2005;23:64–76. Knowler WC, Barrett-Connor E, Fowler SE, et al; Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346:393–403. Koro CE, Bowlin SJ, Bourgeois N, Fedder DO. Glycemic control from 1988 to 2000 among US adults diagnosed with type 2 diabetes: a preliminary report. Diabetes Care. 2004;27:17–20. Mari A, Sallas M, He YL, et al. Vildagliptin, a dipeptidyl peptidase-IV inhibitor, improves model-assessed beta-cell function in patients with type 2 diabetes. J Clin Endocrinol Metab. 2005;90:4888–4894. Mika A, Stashko M, Lubben T, et al. Acute DPP-IV inhibition minimizes glucose and insulin responses to a glucose challenge in a diabetic mouse. Presented at the American Diabetes Association Scientific Sessions, 2003. Abstract 1516-P. Available at: http://scientificsessions.diabetes.org/Abstracts/index.cfm (accessed December 12, 2005). Mimori N, Terao S, Holmes D. Vildagliptin improves glucose control as evidenced by HbA1c after 12 weeks therapy in Japanese patients with type 2 diabetes. Presented at the American Diabetes Association Annual Meeting, 2006. Abstract 527-P. Available at: http://scientificsessions.diabetes.org/ Abstracts/index.cfm (accessed October 11, 2007). Nauck MA, El-Ouaghlidi A. The therapeutic actions of DPP-IV inhibition are not mediated by glucagon-like peptide-1. Diabetologia. 2005;48:608–611. Nauck M, Stockmann F, Ebert R, et al. Reduced incretin effect in type 2 (non-insulin dependent) diabetes. Diabetologia. 1986;29:46–52. Nauck MA, Wollschlager D, Werner J, et al. Effects of subcutaneous glucagon-like peptide 1 (GLP-1[7-36 amide]) in patients with NIDDM. Diabetologia. 1996;39:1546-1553. NICE (National Institute for Health and Clinical Excellence). Clinical guidelines for type 2 diabetes: Management of blood glucose. September 2002. Available at: http://www.nice.org.uk (accessed November 7, 2005). Pan XR, Li GW, Hu YH, et al; The Da Qing IGT and Diabetes Study. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. Diabetes Care. 1997;20:537–544. Pi-Sunyer FX, Schweizer A, Mills D, Dejager S. Efficacy and tolerability of vildagliptin monotherapy in drug-naïve patients with type 2 diabetes. Diabetes Res Clin Pract. 2007;76:132–138. Pinhas-Hamiel O, Zeitler P. The global spread of type 2 diabetes mellitus in children and adolescents. J Pediatr. 2005;146:693–700. 29